

PRESS CUTTINGS

Client : Asterand
Publication: Financial Times
Date : 9 April 2008

PHARMACEUTICALS & BIOTECH

Asterand PLC

Preliminary Results for the year ended 31/12/07

Asterand (LSE: ATD), a leading global supplier of human tissue and human tissue-based research services to the healthcare sector, announces its audited preliminary financial results for the year ended 31/12/07.

Highlights:

- Sales up 9% to £7.6m and costs down 9% at constant exchange rates
- Cash resources of £2.2m with a secured £2m working capital facility

Key contracts announced with:

- US Department of Defense and Bristol Myers Squibb

Board changes:

- Non-Exec appointment of Dr Peter Coggins, former President of PerkinElmer Inc. LAS
- Jack Davis, currently Senior Independent Director elected Chairman at Asterand's forthcoming AGM, 7 May, replacing David Lee, who will not seek re-election.

Martyn Coombs, CEO said: "Asterand has made significant progress towards its strategic objectives of sustained positive cash flow and sales growth securing its position as a leader in the provision of products and services based on usage of human tissue. The stage is set for significant growth in 2008 and beyond."...

<http://announce.ft.com/announce/380717>

